{
    "root": "316a46f1-2d4e-7684-e063-6294a90a2ef8",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Solifenacin Succinate",
    "value": "20250328",
    "ingredients": [
        {
            "name": "SOLIFENACIN SUCCINATE",
            "code": "KKA5DLD701"
        }
    ],
    "indications": "solifenacin succinate tablets indicated treatment adults overactive bladder symptoms urge urinary incontinence , urgency , urinary frequency .",
    "contraindications": "5 mg tablet taken orally daily , well tolerated may increased 10 mg daily . ( 2.1 ) exceed 5 mg dose solifenacin succinate tablets patients : severe renal impairment creatinine clearance < 30 ml/min/1.73 2 . ( 2.2 , 8.6 ) moderate hepatic impairment ( child-pugh b ) . solifenacin succinate tablets recommended patients severe hepatic impairment ( child-pugh c ) . ( 2.3 , 8.7 ) concomitant strong cyp3a4 inhibitors . ( 2.4 , 7.1 )",
    "warningsAndPrecautions": "solifenacin succinate tablets supplied round , film-coated tablets , biconvex , available bottles follows : 5 mg tablet yellow , debossed \u2018 ap28 \u2019 one side plain side available follows : bottle 30 ndc 35561-285-10 bottle 90 ndc 35561-285-11 bottle 500 ndc 35561-285-13 10 mg tablet yellow , debossed \u2018 ap29 \u2019 one side plain side available follows : bottle 30 ndc 35561-286-10 bottle 90 ndc 35561-286-11 bottle 500 ndc 35561-286-13 store 25\u00bac ( 77\u00baf ) excursions permitted 15\u00bac 30\u00bac ( 59\u00b0f 86\u00baf ) [ usp controlled room temperature ] .",
    "adverseReactions": "solifenacin succinate tablets contraindicated patients : urinary retention [ ( 5.2 ) ] , gastric retention [ ( 5.3 ) ] , uncontrolled narrow-angle glaucoma [ ( 5.5 ) ] , demonstrated hypersensitivity solifenacin succinate inactive ingredients solifenacin succinate tablets . reported included anaphylaxis angioedema [ ( 6.2 ) ] .",
    "indications_original": "Solifenacin Succinate Tablets are indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.",
    "contraindications_original": "5 mg tablet taken orally once daily, and if well tolerated may be increased to 10 mg once daily. ( 2.1 ) Do not exceed the 5 mg dose of Solifenacin Succinate Tablets in patients with: Severe renal impairment creatinine clearance < 30 mL/min/1.73 m 2 . ( 2.2 , 8.6 ) Moderate hepatic impairment (Child-Pugh B). Solifenacin Succinate Tablets are not recommended in patients with severe hepatic impairment (Child-Pugh C). ( 2.3 , 8.7 ) Concomitant use of strong CYP3A4 inhibitors. ( 2.4 , 7.1 )",
    "warningsAndPrecautions_original": "Solifenacin Succinate Tablets are supplied as round, film-coated tablets, biconvex, available in bottles as follows:\n                  Each 5 mg tablet is yellow, debossed with \u2018AP28\u2019 on one side and plain on the other side and is available as follows:\n                  Bottle of 30\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 35561-285-10\n                  Bottle of 90\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 35561-285-11\n                  Bottle of 500\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 35561-285-13\n                  \n                  Each 10 mg tablet is yellow, debossed with \u2018AP29\u2019 on one side and plain on the other side and is available as follows:\n                  Bottle of 30\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 35561-286-10\n                  Bottle of 90\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 35561-286-11\n                  Bottle of 500\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 35561-286-13\n                  Store at 25\u00baC (77\u00baF) with excursions permitted from 15\u00baC to 30\u00baC (59\u00b0F to 86\u00baF) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Solifenacin Succinate Tablets are contraindicated in patients:\n                  \n                     With urinary retention \n        \n  \n   [see \n         \n   \n    Warnings and Precautions (5.2)]\n        \n  \n   ,\n       \n \n  \n                     With gastric retention \n        \n  \n   [see \n         \n   \n    Warnings and Precautions (5.3)]\n        \n  \n   ,\n       \n \n  \n                     With uncontrolled narrow-angle glaucoma \n        \n  \n   [see \n         \n   \n    Warnings and Precautions (5.5)]\n        \n  \n   , and\n       \n \n  \n                     Who have demonstrated hypersensitivity to solifenacin succinate or the inactive ingredients in Solifenacin Succinate Tablets. Reported adverse reactions have included anaphylaxis and angioedema \n        \n  \n   [see \n         \n   \n    Adverse Reactions (6.2)]\n        \n  \n   ."
}